Petzer Andreas L, Gunsilius Eberhard, Hayes Michael, Stockhammer Guenther, Duba Hans C H, Schneller Folker, Grünewald Kurt, Poewe Werner, Gastl Guenther
Abteilung für Hämatologie & Onkologie, Universitätsklinik Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria.
Br J Haematol. 2002 Jun;117(3):623-5. doi: 10.1046/j.1365-2141.2002.03523.x.
We report a 53-year-old man with lymphoid blast crisis of Ph+ chronic myeloid leukaemia who was treated with STI571, a selective inhibitor of the enzymatic activity of BCR-ABL. He responded excellently to STI571 (600 mg/d), obtaining a complete cytogenetic remission after 3 months of therapy. Although remission in the bone marrow was sustained, the patient developed an isolated central nervous system relapse. Subsequent analyses of STI571 concentrations in the cerebrospinal fluid (CSF) revealed 2-log lower CSF levels of STI571 than corresponding plasma levels. These are the first data demonstrating a low penetration of orally administered STI571 into the CSF in humans.
我们报告了一名53岁患有Ph+慢性髓性白血病淋巴母细胞危象的男性患者，其接受了STI571（一种BCR-ABL酶活性的选择性抑制剂）治疗。他对STI571（600mg/天）反应良好，治疗3个月后获得了完全细胞遗传学缓解。尽管骨髓缓解得以维持，但该患者出现了孤立的中枢神经系统复发。随后对脑脊液（CSF）中STI571浓度的分析显示，CSF中STI571水平比相应血浆水平低2个对数。这些是首次证明口服STI571在人体中进入CSF的渗透率较低的数据。
